DOI

Detection Principle

ImmunoAssay-Antibody

Target

IgA, IgM, IgG

Testing Method Category

Other Immuno assay

Testing Method

SARS-CoV-2 IgG assay (Abbott Laboratories, Abbott Park, IL, USA), SARS-CoV-2 S1/S2 IgG (DiaSorin, Stillwater, MN, USA), COVID-19 IgM and IgG ELISA (Epitope Diagnostics Inc., supplied by Affinity Diagnostics Corp., Toronto, ON, Canada), COVID-19 IgM and IgG assay (DRG International Inc., supplied by Bio-Rad, Hercules, CA, USA), anti-SARS-CoV-2 ELISA IgA and IgG assay (Euroimmun, Mississauga, ON, Canada), ECLIA anti-SARS-CoV-2 (Roche Diagnostics, Indianapolis, IN, USA), Rapid Response (BTNX, Markham, Ontario, Canada), 2019 nCoV IgM/IgG detection kit (Biolidics Limited, Singapore), SARS-CoV-2 IgG/IgM Ab test kit (Anhui Deep Blue Medical Technology Co., Ltd., Anhui, China), Novel Coronavirus IgG/IgM test kit (Genrui; Genrui Biotech Inc., Shenzhen, China), One Step Test for Novel Coronavirus (Getein Biotech Inc., Nanjing, China), and the 2019-nCoV Ab test (Innovita Biological Technology Co. Ltd., Qian'an, Hebei, China)

Testing Method - Additional Info

Comparison of commercial chemiluminescence immunoassays (CLIA), enzyme-linked immunosorbent assays (ELISA), electrochemiluminescence immunoassay (ECLIA), point-of-care lateral flow tests (POCTs)

Reported Performance

Sensitivity (all time points): 81% (Abbott), 68-95% (Affinity), 55-88% (Biorad), 62% (Diasorin), 63-83% (Euroimmun), 71% (Roche), 50-75% (BTNX), 18-78% (Biolidics), 53-70% (Deep Blue), 65-80% (Genrui), 3-64% (Getein), 20-45% (Innovita) ; Precision (all EIAs): 100% ; Reproducibility (all EIAs): 100% ; Remarks: sample size varies for different performance studies, percentages range among different target antibodies

Sample Size

96 samples

Peer-reviewed

yes